Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AZD9977 Formulations and Food Effect in Healthy Males
NCT02560363Phase 1Withdrawn
- Sponsor
- AstraZeneca
- Start
- Nov 2015
- Primary completion
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of balcinrenone in heart failure (HF) and chronic kidney disease (CKD) (4 arms), sponsored by AstraZeneca. Primary endpoints: Area Under the Curve, Area Under the Curve from time 0 to last measurable concentration and 2 more. Planned start Nov 2015; status: withdrawn.
02
Drugs
balcinrenone
03
Conditions
heart failure (HF)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT02560363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02560363.